Guidelines on Male Sexual Dysfunction: Erectile Dysfunction and Premature Ejaculation

Hatzimouratidis, Konstantinos; Amar, Edouard; Eardley, Ian; Giuliano, François; Hatzichristou, Dimitrios; Montorsi, Francesco; Vardi, Yoram; Wespes, Eric

doi:10.1016/j.eururo.2010.02.020

Cited by 999 publications

(1,022 citation statements)

References 51 publications

Supporting

Mentioning

942

Contrasting

Unclassified

Order By: Relevance

“…32 Pain at ejaculation and macroscopic haemospermia were assessed at all time points during patient interviews held by the same physician to minimize evaluation bias. Premature ejaculation was evaluated on the basis of self-estimated intravaginal ejaculatory latency time, perceived control, and reported personal and relational distress, in agreement with Hatzimouratidis et al 33 Persistence of erectile dysfunction (ED) after antibacterial therapy was defined as an IIEF ED score (the sum of IIEF questions 1, 2, 3, 4, 5 and 15) , 26. 32 Data handling and statistical analysis To test null hypotheses about intragroup differences in the NIH-CPSI and IIEF scores, we processed our data in the form of ordinal dominance matrices and calculated the Cliff's delta (h) for paired data, 34 the asymmetric 95% confidence interval (CI) to h (calculated using the improved formula by Feng and Cliff 35 ), and the cumulative probability of z (z5h/ ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi ffi unbiased estimated variance of L p ).…”

Section: Evaluation Of Sexual Dysfunctionmentioning

confidence: 99%

Fluoroquinolone–macrolide combination therapy for chronic bacterial prostatitis: retrospective analysis of pathogen eradication rates, inflammatory findings and sexual dysfunction

Magri¹,

Montanari²,

Škerk³

et al. 2011

Asian J Androl

View full text Add to dashboard Cite

We previously demonstrated the safety and efficacy of fluoroquinolone-macrolide combination therapy in category II chronic bacterial prostatitis (CBP). The aim of this study is to retrospectively compare the microbiological and clinical findings of two treatment schemes for CBP based on the combination of azithromycin (500 mg, thrice-weekly) with a once-daily 500-or 750-mg dose of ciprofloxacin (Cipro-500 or Cipro-750 cohort, respectively). Combined administration of azithromycin (1500 mg week 21 ) with ciprofloxacin at the rate of 750 mg day 21 for 4 weeks rather than at 500 mg day 21 for 6 weeks increased the eradication rates from 62.35% to 77.32% and the total bacteriological success from 71.76% to 85.57%. A significant decrease in pain and voiding signs/symptoms and a significant reduction in inflammatory leukocyte counts and serum prostate-specific antigen (PSA) were sustained throughout an 18-month follow-up period in both groups. Ejaculatory pain, haemospermia and premature ejaculation were significantly attenuated on microbiological eradication in both groups, but the latter subsided more promptly in the Cipro-750 cohort. In total, 59 Cipro-750 patients showed mild-to-severe erectile dysfunction (ED) at baseline, while 22 patients had no ED on microbiological eradication and throughout the follow-up period. In conclusion fluoroquinolone-macrolide therapy resulted in pathogen eradication and CBP symptom attenuation, including pain, voiding disturbances and sexual dysfunction. A once-daily 750-mg dose of ciprofloxacin for 4 weeks showed enhanced eradication rates and lower inflammatory white blood cell counts compared to the 500-mg dose for 6 weeks. Our results are open to further prospective validation.

show abstract

Section: Evaluation Of Sexual Dysfunctionmentioning

confidence: 99%

Fluoroquinolone–macrolide combination therapy for chronic bacterial prostatitis: retrospective analysis of pathogen eradication rates, inflammatory findings and sexual dysfunction

Magri¹,

Montanari²,

Škerk³

et al. 2011

Asian J Androl

View full text Add to dashboard Cite

show abstract

“…Dapoxetine hydrochloride (Priligy; Janssen Pharmaceutica NV, Beerse, Belgium), a selective serotonin reuptake inhibitor (SSRI), was the first drug originally approved for the ondemand treatment of premature ejaculation (PE) by seven European countries (Austria, Finland, Germany, Italy, Portugal, Spain, and Sweden) in 2008 [1]. Since then, it has received marketing authorization in 59 countries worldwide.…”

Section: Introductionmentioning

confidence: 99%

Results from a Prospective Observational Study of Men with Premature Ejaculation Treated with Dapoxetine or Alternative Care: The PAUSE Study

et al. 2014

View full text Add to dashboard Cite

“…11 At present, a 1 -blocker monotherapy is highly recommended for the treatment of LUTS/ BPH, 12 and PDE5i are a first-line treatment for ED. 13 Given this, it is important to understand the safety and efficacy of PDE5i/a 1 -blocker combination therapy in patients with concurrent LUTS/BPH and ED, particularly with regard to hypotension hemodynamic interactions. Indeed, several studies with middle-aged patients with LUTS/BPH and ED have shown that combination therapy with PDE5i and a 1 -blockers improve the symptoms of both ED and LUTS/BPH without inducing any hypotensive hemodynamic interactions.…”

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of combination therapy with mirodenafil and α1-blocker for benign prostatic hyperplasia-induced lower urinary tract symptoms accompanied by erectile dysfunction: a multicenter, open-label, prospective study

Lee

Cho

et al. 2011

Int J Impot Res

View full text Add to dashboard Cite

This study was conducted to determine whether mirodenafil 100 mg, when administered on demand to patients with benign prostatic hyperplasia (BPH) who are receiving a 1 -blocker therapy, is safe with regard to the cardiovascular system and whether it improves lower urinary tract symptoms (LUTS) and sexual function. The study involved 121 LUTS/BPH patients who had been treated for at least 3 months with a 1 -blockers before being administered with mirodenafil 100 mg on demand. Before the start of mirodenafil administration, the blood pressure, heart rate, international prostate symptom score (IPSS)/quality of life (QoL), peak urine flow rate (Qmax), post-voiding residual urine volume (PVR), and international index of erectile function-5 (IIEF-5) of each patient were measured. At 4 and 8 weeks after commencing mirodenafil administration, the blood pressure and heart rate were measured again, any adverse effects of mirodenafil were assessed, and sexual function and voiding symptoms were re-evaluated. Of the 121 patients, 73 (60.3%) completed the 8-week clinical trial. Significant changes in blood pressure and heart rate were not observed during the study. Significant improvements in the IIEF-5 and the IPSS/QoL, but not the Qmax or PVR, were observed. The results of this study suggest that the administration of mirodenafil 100 mg on demand may induce few hypotensive interactions and may be acceptably effective with regard to improving LUTS and sexual function.

show abstract

Guidelines on Male Sexual Dysfunction: Erectile Dysfunction and Premature Ejaculation

Cited by 999 publications

References 51 publications

Fluoroquinolone–macrolide combination therapy for chronic bacterial prostatitis: retrospective analysis of pathogen eradication rates, inflammatory findings and sexual dysfunction

Fluoroquinolone–macrolide combination therapy for chronic bacterial prostatitis: retrospective analysis of pathogen eradication rates, inflammatory findings and sexual dysfunction

Results from a Prospective Observational Study of Men with Premature Ejaculation Treated with Dapoxetine or Alternative Care: The PAUSE Study

Efficacy and safety of combination therapy with mirodenafil and α1-blocker for benign prostatic hyperplasia-induced lower urinary tract symptoms accompanied by erectile dysfunction: a multicenter, open-label, prospective study

Contact Info

Product

Resources

About